Literature DB >> 10933655

In vitro antibiotic susceptibility of Francisella tularensis isolated from humans and animals.

I Ikäheimo1, H Syrjälä, J Karhukorpi, R Schildt, M Koskela.   

Abstract

The in vitro susceptibility of 38 strains of Francisella tularensis (biovar F. tularensis palaearctica) was determined using Etests on cysteine heart agar plates with 2% haemoglobin. All strains were susceptible to the antibiotics traditionally used to treat tularaemia, such as streptomycin (MIC(90) 4.0 mg/L), tetracycline (MIC(90) 0.38 mg/L) and chloramphenicol (MIC(90) 0.38 mg/L), and to aminoglycosides, such as tobramycin (MIC(90) 1.5 mg/L) and gentamicin (MIC(90) 1.0 mg/L). The quinolones examined had low MIC(90)s: ciprofloxacin, 0.016 mg/L; levofloxacin, 0.016 mg/L; grepafloxacin, 0.047 mg/L; and trovafloxacin, 0.032 mg/L. In contrast, all the strains were resistant to beta-lactams and azithromycin. Quinolones thus seem to be promising drugs for the treatment of tularaemia.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10933655     DOI: 10.1093/jac/46.2.287

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  23 in total

1.  Broth microdilution susceptibility testing of Francisella tularensis: quality control limits for nine antimicrobial agents and three standard quality control strains.

Authors:  Steven D Brown; Karen Krisher; Maria M Traczewski
Journal:  J Clin Microbiol       Date:  2004-12       Impact factor: 5.948

2.  Formulation and stabilization of Francisella tularensis live vaccine strain.

Authors:  Satoshi Ohtake; Russell A Martin; Atul Saxena; David Lechuga-Ballesteros; Araceli E Santiago; Eileen M Barry; Vu Truong-Le
Journal:  J Pharm Sci       Date:  2011-04-13       Impact factor: 3.534

3.  Screen of FDA-approved drug library identifies maprotiline, an antibiofilm and antivirulence compound with QseC sensor-kinase dependent activity in Francisella novicida.

Authors:  Scott N Dean; Monique L van Hoek
Journal:  Virulence       Date:  2015       Impact factor: 5.882

4.  In vitro susceptibility of isolates of Francisella tularensis types A and B from North America.

Authors:  Sandra K Urich; Jeannine M Petersen
Journal:  Antimicrob Agents Chemother       Date:  2008-04-14       Impact factor: 5.191

5.  Structure of the Francisella response regulator QseB receiver domain, and characterization of QseB inhibition by antibiofilm 2-aminoimidazole-based compounds.

Authors:  Morgan E Milton; C Leigh Allen; Erik A Feldmann; Benjamin G Bobay; David K Jung; Matthew D Stephens; Roberta J Melander; Kelly E Theisen; Daina Zeng; Richele J Thompson; Christian Melander; John Cavanagh
Journal:  Mol Microbiol       Date:  2017-08-16       Impact factor: 3.501

Review 6.  Aminoglycosides: An Overview.

Authors:  Kevin M Krause; Alisa W Serio; Timothy R Kane; Lynn E Connolly
Journal:  Cold Spring Harb Perspect Med       Date:  2016-06-01       Impact factor: 6.915

7.  Benzimidazole-based antibacterial agents against Francisella tularensis.

Authors:  Kunal Kumar; Divya Awasthi; Seung-Yub Lee; Jason E Cummings; Susan E Knudson; Richard A Slayden; Iwao Ojima
Journal:  Bioorg Med Chem       Date:  2013-04-03       Impact factor: 3.641

8.  Invasion of erythrocytes by Francisella tularensis.

Authors:  Joseph Horzempa; Dawn M O'Dee; Donna Beer Stolz; Jonathan M Franks; Doris Clay; Gerard J Nau
Journal:  J Infect Dis       Date:  2011-07-01       Impact factor: 5.226

9.  Azithromycin effectiveness against intracellular infections of Francisella.

Authors:  Saira Ahmad; Lyman Hunter; Aiping Qin; Barbara J Mann; Monique L van Hoek
Journal:  BMC Microbiol       Date:  2010-04-23       Impact factor: 3.605

10.  Francisella novicida bacteremia, Thailand.

Authors:  Amornrut Leelaporn; Samaporn Yongyod; Sunee Limsrivanichakorn; Thitiya Yungyuen; Pattarachai Kiratisin
Journal:  Emerg Infect Dis       Date:  2008-12       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.